AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

The Financial Times reports that AstraZeneca and Bristol Myers Squibb are in talks about a potential four hundred billion dollar merger. The deal would combine the U.K.-based AstraZeneca with its U.S. rival.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton